scispace - formally typeset
C

Carlos Cordon-Cardo

Researcher at Icahn School of Medicine at Mount Sinai

Publications -  620
Citations -  91832

Carlos Cordon-Cardo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 144, co-authored 589 publications receiving 84862 citations. Previous affiliations of Carlos Cordon-Cardo include The Rogosin Institute & Erasmus University Rotterdam.

Papers
More filters
Posted ContentDOI

Cellular and molecular heterogeneities and signatures, and pathological trajectories of fatal COVID-19 lungs defined by spatial single-cell transcriptome analysis

TL;DR: In this paper , the authors examined postmortem COVID-19 lung tissues by spatial single-cell transcriptome analysis (SSCTA) and identified 18 major parenchymal and immune cell types, all of which are infected by SARS-CoV-2.
Journal ArticleDOI

Creating surveillance data infrastructure using laboratory analytics: Leveraging visiun and epic systems to support COVID-19 pandemic response

TL;DR: The key components of a conceptual surveillance framework required for a robust response to COVID-19 pandemics are reviewed and demonstrated leveraging a lab analytics dashboard, Visiun, combined with Epic reporting tools to function as a surveillance system.
Journal ArticleDOI

Characteristics Associated With Disparities Among Older Adults in Coronavirus Disease 2019 Outcomes in an Academic Health Care System

TL;DR: Examination of patient and health system factors predictive of in-hospital mortality, intensive care unit (ICU) admission, and readmission among patients with COVID-19 found increased age was the single greatest independent risk factor for mortality.

Thymidylate S ynthase E xpression i n H epatic T umors I s a Predictor o f S urvival a nd P rogression i n P atients W ith Resectable M etastatic C olorectal C ancer

TL;DR: TS levels in hepatic tumors and resection margin are independent predictors of survival and progression in patients with metastatic colorectal cancer, whereas p53 and EGFR are not independent predictor.